NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india) arrow 11642.30 47.85 0.41%
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Dyax Corp. (NASDAQ: DYAX)

 
DYAX Technical Analysis
5
As on 21st Jan 2016 DYAX Share Price closed @ 38.41 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 26.49 & Strong Buy for SHORT-TERM with Stoploss of 36.25 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

DYAX Share Price

Open 38.36 Change Price %
High 38.56 1 Day 0.10 0.26
Low 38.25 1 Week 0.00 0.00
Close 38.41 1 Month 0.00 0.00
Volume 12524978 1 Year 0.00 0.00
52 Week High 5.20 | 52 Week Low 3.25
 
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
INTC 45.49 2.52%
 
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
 
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
 
 
DYAX
Daily Charts
DYAX
Intraday Charts
Whats New @
Bazaartrend
DYAX
Free Analysis
 
DYAX Important Levels Intraday
SUPPORT0.00
SUPPORT0.00
RESISTANCE38.70
RESISTANCE38.58
SUPPORT38.24
SUPPORT38.12
SUPPORT0.00
SUPPORT0.00
 
DYAX Target for Month April
4th UP TARGET0
3rd UP TARGET0
2nd UP TARGET0
1st UP TARGET0
1st DOWN TARGET0
2nd DOWN TARGET0
3rd DOWN TARGET0
4th DOWN TARGET0
 
DYAX Weekly Target
4th UP TARGET0.00
3rd UP TARGET0.00
2nd UP TARGET0.00
1st UP TARGET0.00
1st DOWN TARGET0.00
2nd DOWN TARGET0.00
3rd DOWN TARGET0.00
4th DOWN TARGET0.00
 
DYAX Target for Year 2019
4th UP TARGET0
3rd UP TARGET0
2nd UP TARGET0
1st UP TARGET0
1st DOWN TARGET0
2nd DOWN TARGET0
3rd DOWN TARGET0
4th DOWN TARGET0
 
 
DYAX Other Details
Segment EQ
Market Capital 315442656.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.dyax.com
 
DYAX Address
DYAX
55 Network Drive
Burlington, MA 01803
United States
Phone: 617-225-2500
Fax: 617-225-2501
 
DYAX Latest News
 
Your Comments and Response on Dyax Corp.
 
DYAX Business Profile
Dyax Corp. (Dyax), is a biopharmaceutical company with two business elements: Angioedema Franchise and Phage Display Licensing and Funded Research Program. It is focused on identifying and developing treatments for patients who experience plasma kallikrein (bradykinin) mediated angioedema. The principal focus of Dyax is to identify, develop and commercialize treatments for conditions identified as plasma kallikrein (bradykinin) mediated angioedema, including hereditary angioedema (HAE), ACE inhibitor-induced angioedema (ACEI-AE) and angioedema of unknown origin, or idiopathic angioedema. It developed KALBITOR (ecallantide) on its own in the United States for the treatment of acute attacks of HAE. Outside of the United States, it has established partnerships to obtain regulatory approval for and commercialize KALBITOR in certain markets and it is evaluating opportunities in others. It leverages its phage display technology through the Licensing and Funded Research Program (LFRP).
 
2005-2019 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service